GAZYVA in combination with chlorambucil caused Grade 3 or 4 neutropenia in 34% of patients
in the trial. Patients with Grade 3 to 4 neutropenia should be monitored frequently with regular
laboratory tests until resolution. Anticipate, evaluate, and treat any symptoms or signs of
developing infection.
Neutropenia can also be of late onset (occurring more than 28 days after completion of
treatment) and/or prolonged (lasting longer than 28 days).
Patients with neutropenia are strongly recommended to receive antimicrobial prophylaxis
throughout the treatment period. Antiviral and antifungal prophylaxis should be considered.